Remegen is a leading biotech company focused on discovering and developing a new generation of targeted therapies that advance treatments for cancer, eye and autoimmune diseases.
RemeGen is fully integrated capabilities in research and discovery, clinical development, manufacturing and commercialization of biologic drugs.
RemeGen was founded in 2008 by Jianmin Fang. The company is headquartered in Yantai, Shangdong Province, China.
RemeGen is dedicated to fulfilling unmet medical needs for patients with life-threatening conditions.
RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates. The company's rich pipeline of innovative drugs, with over 15 indications, is designed to address significant unmet medical needs.
RemeGen has created more than 10 novel drug molecules that are in various stages of clinical development. Currently, there are two products in late stage clinical development to treat autoimmune and oncology indications.
RemeGen has raised $100M in a private financing on April 02, 2020. The round was co-led by Lilly Asia Ventures and Lake Bleu Capital. Vivo Capital, Janchor Partners, OrbiMed, Hudson Bay Capital and the company's existing investors. Loyal Valley Capital and China Reform Conson Soochow Overseas Fund also invested through the purchase from existing shareholders.